Global Dual Chamber Prefilled Syringe Market - 2024-2031

Global Dual Chamber Prefilled Syringe Market - 2024-2031

The dual chamber prefilled syringe market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

The dual chamber prefilled syringes are intended to contain and administer two distinct substances, such as a diluent and the active ingredient (drug), which need to be maintained apart until the time of delivery. These syringes are more convenient and effective at mixing and delivering the two chemicals than conventional single-chamber syringes.

There is a barrier between the two chambers, like a plunger or breakable seal, that can be readily manipulated to allow the contents to be mixed right before use. Dual chamber prefilled syringes are designed to minimize the chance of premature mixing, guarantee accurate dosing, and preserve the stability and effectiveness of each component until the administration. This novel technique solves problems with drug stability, compatibility, and shelf life while offering a dependable means of dispensing many agents simultaneously.

These syringes are widely employed in medicine for a variety of purposes, such as complex medication reconstitution and administration, vaccines, biologics, and other formulations that require sensitivity.

Market Dynamics: Drivers

Growing demand for biologics and biosimilars

The dual chamber prefilled syringe market is expanding by various factors. Biologics are ideal for focused distribution and inclination boosting because they are less prone to combine with other medications. Because more biologics are being utilized to treat chronic illnesses, manufacturers of medicines and packaging are under pressure to create more sophisticated systems for drug delivery and container closure.

In addition, the rising usage of these prefilled syringes and self-administration of biologics and biosimilars would drive the market. As per NCBI publication in 2023, 98 biosimilars have been approved in India under CDSCO.

The growing need for biological drugs and the developing developments in injectable delivery techniques are projected to propel the growth of the global dual chamber prefilled syringes market.

The market would be driven by the strategies of major industry players, such as innovations. The approval of the supplementary biologics applications for the self-injectable dual chamber prefilled syringe of Xolair by the FDA in 2021 marked a significant milestone for F. Hoffman-La Roche Ltd.

Moreover, increased biological drug approvals would drive the market. An NCBI research report states that the FDA authorized 37 distinct drugs in 2022. These customized delivery methods, which improve patient and healthcare provider convenience, safety, and user experience, have grown to be a crucial component of the expanding biologics and biosimilar business. Some instances of dual chamber prefilled syringe products for biologics and biosimilars include Enbrel, Humira, Simponi, and Benepali.

Restraints

Factors such as product recalls, the requirement of high capital investment for setting up manufacturing facilities, stringent government regulatory guidelines, the threat of counterfeit products posing risk to the patients & availability of alternative medicine delivery techniques, extensive research and development initiatives, limited adoption of specialized separable chambers are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The dual chamber prefilled syringe market is segmented based on product type, type, material type, form, application, distribution channel and region.

The conventional prefilled syringes segment accounted for approximately 64.3% of the dual chamber prefilled syringe market share

The conventional prefilled syringes segment is expected to hold the largest market share over the forecast period. A single chamber of these prefilled syringes is filled with a precise amount of biological medication. These easy-to-use gadgets offer a dependable and practical way to safely and precisely deliver prescription drugs.

Both individuals and medical professionals who have used conventional prefilled syringes for a long time are familiar with their straightforward design and application procedure. The U.S. FDA-approved Genentech's Avastin (Bevacizumab), another cancer medication, for use with a prefilled syringe in May 2021. This drug is a humanized monoclonal recombinant IgG1 antibody that is used to treat different kinds of cancer.

Both individuals and medical professionals have used conventional prefilled syringes for a long time for medication procedures. In May 2021, Genentech got U.S. FDA approval for the Avastin prefilled syringe for cancer medication. This medication is an artificial monoclonal antibody that is used to treat various types of cancer.

This offers a comfort level and smooth workflow integration as compared to relatively new safety-prefilled syringes. The straightforward filling and delivery mechanism of conventional prefilled syringes allows for swift administration without additional steps compared to safety variants. This makes them particularly suitable for situations requiring rapid treatment such as emergency rooms.

Moreover, market key players launch innovative products, and mergers and acquisitions help to drive this segment in the market. For instance, in October 2021, In collaboration with Aptar Pharma, BD introduced the BD SCF premium coat Plunger to enable the injection of biologics using syringes.

Also, in April 2021, Nipro Pharma Packaging International announced that the Nipro D2F pre-filled syringes are compatible with the Schreiner MediPharm needle trap, expanding the range of products offered to drive the market growth.

Geographical Analysis

North America accounted for approximately 42.3% of the dual chamber prefilled syringe market share

North America region is expected to hold the largest market share over the forecast period. This dominance can be attributed to the aging population, which has created a surge in demand for various medical solutions, including dual chamber prefilled syringes, catering to the needs of patients with complex treatment regimens, significant medical device manufacturing capacity, and increased per capita healthcare spending is vital in pushing the market growth. As individuals become more health-conscious and the healthcare infrastructure advances drive the market growth in this region.

In addition, the industry's major player launches innovative products to drive market growth. For instance, on June 23, 2023, the Hikma Pharmaceutical Industry introduced the Neostigmine Injection in a prefilled syringe format. This innovation caters to the growing demand for convenient and ready-to-use medication delivery systems.

Moreover, key manufacturers such as Pfizer, Bayer, and others with significant investments in dual chamber technology ensure robust supply and demand in this region. In addition, North America has a stringent regulatory approval pathway for combination products U.S. FDA. drives the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the dual chamber prefilled syringe market. The demand for dual chamber prefilled syringes has expanded dramatically due to the pandemic's requirement for user-friendly and secure drug administration strategies.

The market for dual chamber prefilled syringes is not immediately impacted by COVID-19, but supply disruption is projected to have consequences soon. The prefilled syringes industry has been the most affected since the pandemic. Healthcare providers have embraced telemedicine, which helps eliminate face-to-face interaction, as a market for new and different means of delivering the proper quantity of care.

Furthermore, applications that aid in the self-management of chronic conditions have become popular. Growing investments from public bodies, notably worldwide governments, are predicted to create substantial growth and expansion possibilities for the dual chamber prefilled syringe market.

Market Segmentation

By Product Type
• Conventional Prefilled Syringes
• Safety Prefilled Syringes

By Type
• <1 ML
• 1-2.5 ML
• >5 ML

By Material Type
• Glass
• Plastic

By Form
• Liquid/Liquid
• Liquid/Powder

By Application
• Hemophilia
• Schizophrenia
• Diabetes
• Others

By Distribution Channel
• Liquid/Powder
• Pharmaceutical Manufacturing Companies
• Hospitals & Retail Pharmacies
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the dual chamber prefilled syringe market include BD, Haselmeier, SCHOTT Pharma AG & Co, ARTE Corporation, MAEDA INDUSTRY Co., Ltd., Gerresheimer AG, Pfizer Inc., NIPRO, Credence MedSystems, Inc., Vetter among others.

Key Developments

 In February 2024, Hikma Pharmaceuticals PLC launched a Fentanyl Citrate injection, USP, in 250 mcg/0.5Ml and 50 mcg/ml doses.

 In May 2023, SCHOTT Pharma, a manufacturer of primary packaging solutions, launched prefilled syringes made from advanced polymers for delivering deep cold drugs, which are designed the syringes from an advanced pharmaceutical grade polymer, delivered in standardized nest and tub configuration.

 In October 2022, collaborative efforts between German packing supplier Gerresheimer and pharmaceutical company Merck resulted in the development of a cutting-edge digital twin solution aimed at revolutionizing the pharmaceutical supply chain.

 In September 2022, BD introduced a next-generation glass prefilled syringe that sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination, and integrity.

Why Purchase the Report??
• To visualize the dual chamber prefilled syringe market segmentation based on product type, type, material type, form, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of dual chamber prefilled syringe market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The dual chamber prefilled syringe market report would provide approximately 86 tables, 80 figures, and 184 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies